Editas Medicine Inc.

NAS: EDIT

GO
/marketstate/country/us

After Hours

/zigman2/quotes/200426846/composite

$

18.15

Change

0.00 0.00%

Volume

Volume 44,191

Jan 21, 2022, 4:02 p.m.

Real time quotes

/zigman2/quotes/200426846/composite

Today's close

$ 18.79

$ 18.15

Change

-0.64 -3.41%

Day low

Day high

$18.11

$19.66

Open
Open: 18.48

52 week low

52 week high

$18.11

$73.03

Open

Market cap

$1.29B

Average volume

1.48M

P/E ratio

N/A

Rev. per Employee

$104,230

EPS

-3.25

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/edit

MarketWatch News on EDIT

  1. bluebird bio Has Good News on Its Gene Therapies

    12:16 p.m. Dec. 13, 2021

    - Barron's Online

  2. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  3. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  4. The Man Behind Moderna on What’s Next in Biotech

    10:49 p.m. Oct. 15, 2021

    - Barron's Online

  5. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    6:37 a.m. Sept. 27, 2021

    - Barron's Online

  6. Editas Medicine started at hold with $65 stock price target at Stifel Nicolaus

    6:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  7. Editas Medicine upgraded to outperform from perform at Oppenheimer

    6:28 a.m. Sept. 10, 2021

    - Tomi Kilgore

  8. Editas Medicine upgraded to buy from hold at Truist

    7:11 a.m. Aug. 9, 2021

    - Tomi Kilgore

  9. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    8:21 a.m. June 30, 2021

    - Barron's Online

  10. First In-Vivo Gene Editing Data Look Good for Intellia

    7:40 a.m. June 28, 2021

    - Barron's Online

  11. How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks

    12:38 p.m. June 7, 2021

    - Barron's Online

  12. Why ARK Innovation Is a Different Fund Today Than It Was a Year Ago

    6:24 a.m. March 29, 2021

    - Barron's Online

  13. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  14. Editas Medicine downgraded to hold from buy at Truist

    8:05 a.m. Feb. 26, 2021

    - Tomi Kilgore

  15. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/edit

Other News on EDIT

  1. It's Time To Go To Cash For The Next 7 Years - 1-Year Update

    2:41 p.m. Jan. 20, 2022

    - Seeking Alpha

  2. Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

    10:46 a.m. Jan. 19, 2022

    - Zacks.com

  3. Why Editas Medicine Stock Is Tumbling This Week

    5:24 p.m. Jan. 13, 2022

    - Motley Fool

  4. Genomic Medicine 2021: (Happy To) Turn The Page

    9:33 p.m. Jan. 4, 2022

    - Seeking Alpha

  5. The State Of Biotech In 2022

    4:04 a.m. Jan. 3, 2022

    - Seeking Alpha

  6. Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU

    11:16 a.m. Dec. 15, 2021

    - Zacks.com

  7. Loading more headlines...

Earnings Announcement

/news/pressrelease/company/us/edit

Press Releases on EDIT

  1. Aadi Bioscience Appoints Emma Reeve to its Board of Directors

    7:00 a.m. Sept. 13, 2021

    - GlobeNewswire

  2. Editas Medicine Names Emma Reeve to Board of Directors

    8:00 a.m. Sept. 8, 2021

    - GlobeNewswire

  3. Editas Medicine to Participate in Upcoming Investor Conferences

    7:00 a.m. Sept. 2, 2021

    - GlobeNewswire

  4. Loading more headlines...

Rates »

Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.